NASDAQ:CYCC
Delisted

Cyclacel Pharmaceuticals Stock Forecast

etoro logo Buy CYCC
*Your capital is at risk
$6.37
+0 (+0%)
At Close: Dec 10, 2025

CYCC Performance

CYCC Dividend Payout History


# Declaration Date Ex-Date Pay Date Amount Yield
1 Apr 29, 2025 Apr 29, 2025 May 01, 2025 $0.150 3.84%
2 Jun 09, 2016 Jul 13, 2016 Aug 01, 2016 $3.00 0.0125%

FAQ

What is the symbol for Cyclacel Pharmaceuticals Stock and on which exchange is it traded?
The symbol for Cyclacel Pharmaceuticals is CYCC and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Cyclacel Pharmaceuticals Stock?
Cyclacel Pharmaceuticals holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Cyclacel Pharmaceuticals Stock?
Cyclacel Pharmaceuticals Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Cyclacel Pharmaceuticals Stock.

What's the current price of Cyclacel Pharmaceuticals Stock?
As of the end of day on the Dec 10, 2025, the price of an Cyclacel Pharmaceuticals (CYCC) share was $6.37.

What is the 52-week high and low for Cyclacel Pharmaceuticals Stock?
The 52-week high for Cyclacel Pharmaceuticals Stock is $19.87 and the 52-week low is $0.171.

What is the market capitalization of Cyclacel Pharmaceuticals Stock?
As of the Dec 10, 2025, the market capitalization of Cyclacel Pharmaceuticals is 10.608M.
Click to get the best stock tips daily for free!
ABOUT CYCLACEL PHARMACEUTICALS
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-...
GOLDEN STAR
Ticker Change Signal Date
EAT
$140.46
13.43% Jun 05
TPR
$140.47
4.95% Jun 04
LITE
$905.00
1.83% Jun 01
RUN
$12.83
0.468% May 06
GLBE
$31.61
3.54% May 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE